Research Article
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
Table 2
SVR12 by baseline factors, treatment history, and regimen.
| | Response | Total
(n/N, %) | Treatment-naive
(n/N, %) | Previously treated
(n/N, %) | |
| | Overall (%) | 737/777 (95) | 537/568 (95) | 200/209 (96) | 0.519 | | 95% CI | (93, 96) | (92, 96) | (92, 98) | | | By treatment duration (%) | | | | | | 12 weeks | 613/649 (94) | 477/505 (94) | 136/144 (94) | 0.996 | | 18 weeks | 124/128 (97) | 60/63 (95) | 64/65 (98) | 0.361 | | By regimen (%) | | | | | | Without RBV | 460/485 (95) | 399/420 (95) | 61/65 (94) | 0.761 | | With RBV | 277/292 (95) | 138/148 (93) | 139/144 (97) | 0.204 | | By treatment duration + regimen (%) | | | | | | GZR-EBR 12 weeks | 400/422 (95) | 370/389 (95) | 30/33 (91) | 0.401 | | GZR-EBR + RBV 12 weeks | 213/227 (94) | 107/116 (92) | 106/111 (96) | 0.308 | | GZR-EBR 18 weeks | 60/63 (95) | 29/31 (94) | 31/32 (97) | 0.613 | | GZR-EBR + RBV 18 weeks | 64/65 (99) | 31/32 (97) | 33/33 (100) | 0.492 |
|
|
They were compared between treatment-naïve and previously treated groups.
|
